Analysis | Metabolite Name | Measured Value | Units | Cell Type | Stimulation |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 13071 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 14399 | Peak area | BS4 | Untreated |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 15670 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 16608 | Peak area | BS4 | IFN-G |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 17252 | Peak area | PAK | IFN-G |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 21620 | Peak area | BS4 | TNF-alpha |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 23271 | Peak area | PAK | Untreated |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 24785 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | 30231 | Peak area | HAHA | Untreated |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | Peak area | HAHA | IFN-G | |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | Peak area | HAHA | IL-17A | |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | Peak area | HAHA | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | Peak area | PAK | IL-17A | |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | Peak area | PAK | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M-H)- | Peak area | PAK | TNF-alpha+IL-17A | |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 5513 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 10980 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 11492 | Peak area | HAHA | TNF-alpha |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 11724 | Peak area | HAHA | IL-17A |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 12254 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 13410 | Peak area | PAK | IL-17A |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 13941 | Peak area | PAK | TNF-alpha |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 14504 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 14759 | Peak area | BS4 | TNF-alpha |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | 23245 | Peak area | BS4 | Untreated |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | Peak area | BS4 | IFN-G | |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | Peak area | BS4 | IL-17A | |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | Peak area | HAHA | IFN-G | |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | Peak area | PAK | IFN-G | |
Reversed phase POSITIVE ION MODE | OPHTHALMIC ACID (CAS# 495-27-2); (M+H)+ | Peak area | PAK | Untreated |